Executive Director, Head of Real-World Analytics and Programming

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

The Executive Director, Head of Real-World Analytics and Programming will develop and lead Revolution Medicines’ real-world analytics and programming capability, setting the strategy, operating model, technical standards, and priorities needed to generate rigorous, decision-ready real-world evidence across the product lifecycle.

Reporting to the VP, HEOR/RWE, this leader will partner closely with the Executive Director, Head of Epidemiology & RWD Strategy to align RWD strategy, drive methodologic excellence and optimize the use of data for internal decision making and evidence generation. The role will also collaborate across global and regional HEOR, Clinical Development, Safety, Regulatory, Medical Affairs, Market Access, Commercial Analytics & Insights, and IT to ensure RWE analyses address priority scientific, development, and business needs. Finally, it will be imperative that the ED, RWA&P collaborate strongly with the Development Biostatistics and EU Statistics groups to ensure alignment and overall quality of evidence generation activities.

This is an exceptional opportunity to contribute to the advancement of oncology by leveraging real-world analytics that shape the future of patient care.

The Executive Director will have the following strategic, technical, and leadership responsibilities:

• Set and execute the enterprise strategy and multi-year roadmap for real-world analytics and programming in support of portfolio, Clinical Development, Safety, Medical Affairs, HEOR/RWE, and epidemiology priorities.

• Provide leadership of the cross-functional matrix delivering Medical Affairs interventional studies.

• Lead the assessment and fit-for-purpose use of RWD sources, including claims, electronic health records, registries, genomic/-omics data, and linked datasets; provide guidance on their strengths, limitations, and feasibility for answering priority scientific and business questions.

• Provide scientific and operational leadership for RWE study design, protocol development, statistical analysis planning, programming, interpretation, and final reporting. Ensure delivery of evidence supporting regulatory submissions, product value, and critical development decisions, natural history studies, clinical trial design and optimization, comparative effectiveness and safety studies, healthcare resource utilization studies, post-approval safety studies, and rapid feasibility and landscape assessments.